The State Food and Drug Administration (NMPA) has approved the import registration of Pfizer's new coronavirus treatment drugs with conditions

On February 11, in accordance with the relevant provisions of the Drug Administration Law, the State Food and Drug Administration conducted emergency review and approval in accordance with the special drug approval procedures, and conditionally approved the import registration of Pfizer's new coronavirus treatment drug nematvir tablets/ritonavir tablets combination packaging (i.e., Paxlovid).

This product is an oral small molecule new coronavirus treatment drug, which is used to treat adults with mild to moderate novel coronavirus pneumonia (COVID-19) patients with high-risk factors for progression to severe disease, such as patients with advanced age, chronic kidney disease, diabetes, cardiovascular disease, chronic lung disease and other high-risk factors for severe disease. Patients should strictly follow the instructions under the guidance of a physician, and pay close attention to the interaction information with other drugs listed in the instructions during use.

The State Food and Drug Administration requires the marketing authorization holder to continue to carry out relevant research work, complete the conditional requirements within a time limit, and submit the follow-up research results in a timely manner.